4-Nitro-1-naphthalenamine

Names

[ CAS No. ]:
776-34-1

[ Name ]:
4-Nitro-1-naphthalenamine

[Synonym ]:
EINECS 212-277-7
1-Naphthalenamine, 4-nitro-
4-Nitro-1-naphthalenamine
4-nitronaphthalen-1-amine
MFCD00004026

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
419.0±25.0 °C at 760 mmHg

[ Melting Point ]:
190-193 °C(lit.)

[ Molecular Formula ]:
C₁₀H₈N₂O₂

[ Molecular Weight ]:
188.183

[ Flash Point ]:
207.2±23.2 °C

[ Exact Mass ]:
188.058578

[ PSA ]:
71.84000

[ LogP ]:
2.62

[ Vapour Pressure ]:
0.0±1.0 mmHg at 25°C

[ Index of Refraction ]:
1.729

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: QM4370000

CHEMICAL NAME :: 1-Naphthylamine, 4-nitro-

CAS REGISTRY NUMBER :: 776-34-1

BEILSTEIN REFERENCE NO. :: 2211897

LAST UPDATED :: 199612

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C10-H8-N2-O2

MOLECULAR WEIGHT :: 188.20

WISWESSER LINE NOTATION :: L66J BZ ENW

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

MUTATION DATA

TYPE OF TEST :: Mutation in microorganisms

TEST SYSTEM :: Bacteria - Salmonella typhimurium

DOSE/DURATION :: 25 ug/plate

REFERENCE :: MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 118,49,1983

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H315-H319-H335

[ Precautionary Statements ]:
P261-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xi: Irritant;

[ Risk Phrases ]:
R36/37/38

[ Safety Phrases ]:
S26-S36

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ RTECS ]:
QM4370000

Synthetic Route

Click to get detail synthetic route

Articles

Does P-glycoprotein contribute to amphotericin B epithelial transport in Caco-2 cells?

Drug Dev. Ind. Pharm. 41 , 1130-6, (2015)

Amphotericin B (AmB) is a highly efficacious therapeutic for invasive fungal infections and protozoal diseases. Increasing prevalence of these conditions warrants the development of an oral AmB formul...